HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Physicians Formula Q2

This article was originally published in The Rose Sheet

Executive Summary

Firm reports net sales of $22.1 mil. and $57.8 mil. for the second quarter and first six months of 2007, ended June 30, representing a 4.2% decrease and 13.8% increase, respectively, versus the comparable periods in 2006. Decline in Q2 revenue is attributed partly to higher co-operative advertising expenses and costs associated with the production of an infomercial supporting company's Mineral Wear line and launching nationwide in early 2008, CEO Ingrid Jackel notes during Aug. 13 call. Though it is confident in its position relative to competitors, Physicians Formula has revised its outlook for the remainder of the year due to "an unexpected change in replenishment order patterns of basic stock from [its] top chain drug retailers" - a phenomenon not specific to Physicians Formula but indicative of softer consumer spending for the masstige industry overall, according to the firm. Company now anticipates net sales of $18.5 mil. to $20.5 mil. in Q3, $31 mil. to $33 mil. in Q4 and $107 mil. to $111 mil. for the full year...

You may also be interested in...

Medtronic Faces Surgical Stapler Lawsuits In Minnesota, Texas

Three patients have filed suit against Medtronic in recent weeks alleging they were injured by malfunctioning surgical staplers made by the company. The lawsuits add to recent scrutiny of the device type’s safety.

EU Panel Outlines Practical Way Forward With Big Data

An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.

ViiV Wins Fast-Track Review At EMA For HIV Therapy

A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts